



02-20-07

Attorney's Docket No.: 17083-003002 / 1227B

1FW 1647

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Carlos F. Barbas III et al. Art Unit : 1647
Serial No. : 09/586,625 Examiner : Shulamith H. Shafer
Filed : June 2, 2000 Conf. No. : 6568
Cust. No. : 20985
Title : LIGAND ACTIVATED TRANSCRIPTIONAL REGULATOR PROTEINS

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, Form PTO-1449 (1 page), cited non U.S. patent reference, a check in the amount of \$180.00, and a return postcard for filing in connection with the above-identified application.



The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,


Stephanie Seidman
Reg. No. 33,779


Attorney Docket No. 17083-003002/1227B

Address all correspondence to:

Stephanie L. Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-4777
Facsimile: (202) 626-7796
email: seidman@fr.com

10707995.doc

CERTIFICATE OF MAILING BY "EXPRESS MAIL"
"Express Mail" Mailing Label Number EV 740121350 US
Date of Deposit **February 16, 2007**
I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.


Stephanie Seidman



Attorney's Docket No.: 17083-003002 / 1227B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Carlos F. Barbas III et al. Art Unit : 1646
Serial No. : 09/586,625 Examiner : Joseph F. Murphy
Filed : June 2, 2000 Conf. No. : 6568
Cust. No. : 20985
Title : LIGAND ACTIVATED TRANSCRIPTIONAL REGULATOR PROTEINS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN
ACCORDANCE WITH 37 C.F.R. §§1.97-1.98

Dear Sir:

Because this Supplemental Information Disclosure Statement is after receipt of a first Office Action on the Merits of the above-captioned application, the filing fee of \$180 is enclosed. If no proper payment is enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all information known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (1 page) and a copy of the cited non U.S. patent document are provided herewith in connection with the above-captioned application.

CERTIFICATE OF MAILING BY "EXPRESS MAIL"
"Express Mail" Mailing Label Number EV 740121350 US
Date of Deposit February 16, 2007
I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie Seidman

02/21/2007 MBELETE1 00000068 09586625

01 FC:1806

180.00 0P

Applicant : Carlos F. Barbas III et al.
Serial No. : 09/586,625
Filed : June 2, 2000
Page : 2 of 2


Attorney's Docket No.: 17083-003002 / 1227B

The documents listed on the Form PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed item is necessary.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the information, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97 (g and h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56 (b) exists.

Applicant respectfully requests that the Examiner review the foregoing information and make them of record in the file history of the above-captioned application.

Respectfully submitted,



Stephanie Seidman
Reg. No. 33,729

Attorney Docket No. 17083-003002/1227B

Address all correspondence to:

Stephanie L. Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-4777
Facsimile: (202) 626-7796
email: seidman@fr.com

Substitute Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
17083-003002Application No.
09/586,625**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

Applicant
Carlos F. Barbas III et al.Filing Date
June 2, 2000Group Art Unit
1647**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	6,723,531	04/20/04	Evans et al.	435	69.1	03/16/98

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
		none						

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AB	Robbins, P.D., et al., "Viral vectors for gene therapy," Pharmacology & Therapeutics, 80:35-47, (1998).

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)